Revised the year-end dividend forecast for the fiscal year ending March 2027 to 15 yen per share. No interim dividend was paid. No dividend was paid in the prior fiscal year. Final decision will be made based on future business performance trends.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4506-20261030-05.pdf","jir_short_summary":"Revised the year-end dividend forecast for the fiscal year ending March 2027 to 15 yen per share. No interim dividend was paid. No dividend was paid in the prior fiscal year. Final decision will be made based on future business performance trends.","jir_summary":"### Dividend Policy and Key Points of the Revision\nUnder a policy prioritizing financial soundness and growth investments, the interim dividend was withheld and the year-end dividend for the fiscal year ending March 2027 was initially left undecided. However, based on performance progress through the second quarter and the outlook going forward, the Company has decided to resume shareholder returns. The year-end dividend forecast has been announced as 15 yen per share.\n\n### Risks and Points to Note\nGiven uncertainties in future business performance and external conditions, the dividend forecast may be affected by future performance trends. Attention should be paid to the note in the document stating that \"matters concerning forward-looking statements contain risks and uncertainties,\" among other cautions.","jir_financial_highlights":"Annual Dividend: 15 yen (No prior forecast \/ Revised forecast this time)\nYear-End Dividend Forecast: 15 yen (Prior actual 0 yen \u2192 This time revised (not 0 yen))\nInterim Dividend: No dividend (Continued)","jir_category":"","jir_hashtags":"#SumitomoPharma, #DividendInformation, #ShareholderReturns","jir_key_figures":"Year-end dividend forecast: 15 yen\/share\nInterim dividend: No dividend\nPrior fiscal year actual: 0 yen\/share","jir_meta_title":"Sumitomo Pharma: Notice of Revision to Dividend Forecast | Fiscal Year Ending March 2027","jir_meta_description":"Sumitomo Pharma has revised its year-end dividend forecast for the fiscal year ending March 2027 to 15 yen per share. No interim dividend was paid. The company will reassess based on future business trends. See IR materials for details.","jir_og_title":"Sumitomo Pharma Notice of Revision to Dividend Forecast","jir_og_description":"Sumitomo Pharma has revised its year-end dividend forecast for the fiscal year ending March 2027 to 15 yen per share. No interim dividend was paid. Monitor the outlook.","jir_og_image_url":"\/assets\/og\/company-dividend.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"dividend","footnotes":""},"sector":[],"importance":[],"class_list":["post-138892","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n